Genetic pathways to primary and secondary glioblastoma.

An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36

IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12

The somatic genomic landscape of glioblastoma. Cell (2013) 11.73

Mutual exclusivity analysis identifies oncogenic network modules. Genome Res (2011) 7.22

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol (2009) 6.43

An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene (2009) 4.10

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol (2009) 3.99

Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer (2008) 3.98

Automated network analysis identifies core pathways in glioblastoma. PLoS One (2010) 3.64

Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet (2013) 3.51

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23

Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell (2012) 2.85

The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol (2014) 2.63

Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia (2010) 2.21

Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer (2014) 2.10

A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers. EMBO J (2009) 1.95

Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro Oncol (2008) 1.84

Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet (2011) 1.83

PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev (2010) 1.82

A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A (2010) 1.81

Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma. Mol Cancer (2014) 1.81

Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia (2010) 1.71

Mutant metabolic enzymes are at the origin of gliomas. Cancer Res (2009) 1.66

In silico cancer modeling: is it ready for prime time? Nat Clin Pract Oncol (2008) 1.52

The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int (2015) 1.50

A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol (2012) 1.44

Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS One (2010) 1.44

PDGF and PDGF receptors in glioma. Ups J Med Sci (2012) 1.43

The pathobiology of glioma tumors. Annu Rev Pathol (2010) 1.40

Molecular diagnostics of gliomas: state of the art. Acta Neuropathol (2010) 1.40

PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer (2010) 1.38

Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res (2014) 1.35

Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia (2008) 1.34

Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro Oncol (2010) 1.33

The interface between glial progenitors and gliomas. Acta Neuropathol (2008) 1.33

Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies. Neuro Oncol (2012) 1.32

Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol (2009) 1.32

Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene (2009) 1.31

Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics (2008) 1.31

Proteolytic cleavage of protein tyrosine phosphatase mu regulates glioblastoma cell migration. Cancer Res (2009) 1.30

DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neuro Oncol (2011) 1.29

Recent advances in the molecular understanding of glioblastoma. J Neurooncol (2012) 1.29

Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells. PLoS One (2011) 1.27

A 16-gene signature distinguishes anaplastic astrocytoma from glioblastoma. PLoS One (2014) 1.26

Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis. J Biol Chem (2012) 1.25

A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun (2009) 1.22

Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev (2014) 1.22

ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS One (2012) 1.21

Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res (2008) 1.19

Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int (2014) 1.18

Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neurooncol (2009) 1.17

Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol (2014) 1.17

Activation of neural and pluripotent stem cell signatures correlates with increased malignancy in human glioma. PLoS One (2011) 1.16

Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence. PLoS One (2012) 1.16

A role for the transcription factor HEY1 in glioblastoma. J Cell Mol Med (2008) 1.16

Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia (2010) 1.15

Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. Nat Med (2012) 1.15

Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol (2010) 1.15

ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin Cancer Res (2013) 1.15

Long interspersed element-1 protein expression is a hallmark of many human cancers. Am J Pathol (2014) 1.14

iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype. Mol Cell Proteomics (2009) 1.14

Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest (2012) 1.12

Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas. Diagn Pathol (2012) 1.11

Current data and strategy in glioblastoma multiforme. J Med Life (2010) 1.11

Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. Mol Biosyst (2010) 1.11

Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity. Cancer Biol Ther (2009) 1.10

Association between prediagnostic IgE levels and risk of glioma. J Natl Cancer Inst (2012) 1.10

Metabolism and brain cancer. Clinics (Sao Paulo) (2011) 1.10

The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. EMBO Mol Med (2011) 1.10

Homozygously deleted gene DACH1 regulates tumor-initiating activity of glioma cells. Proc Natl Acad Sci U S A (2011) 1.09

IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS One (2013) 1.08

Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol (2012) 1.08

Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study. Cancer (2008) 1.08

Genomic estimates of aneuploid content in glioblastoma multiforme and improved classification. Clin Cancer Res (2012) 1.06

Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review). Exp Ther Med (2011) 1.05

Impact of MACC1 on human malignant glioma progression and patients' unfavorable prognosis. Neuro Oncol (2013) 1.05

IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci U S A (2009) 1.05

Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stem-like cells. PLoS One (2013) 1.05

Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models. BMB Rep (2011) 1.04

Simulating Brain Tumor Heterogeneity with a Multiscale Agent-Based Model: Linking Molecular Signatures, Phenotypes and Expansion Rate. Math Comput Model (2009) 1.04

Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas. Cancer Res (2011) 1.04

MiR-328 promotes glioma cell invasion via SFRP1-dependent Wnt-signaling activation. Neuro Oncol (2013) 1.04

Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies. J Neurooncol (2010) 1.03

Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol Cancer (2009) 1.03

PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro Oncol (2012) 1.03

Allelic selection of amplicons in glioblastoma revealed by combining somatic and germline analysis. PLoS Genet (2010) 1.02

MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. Neuro Oncol (2012) 1.02

Loss of heterozygosity of TRIM3 in malignant gliomas. BMC Cancer (2009) 1.01

p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res (2008) 1.01

A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples. J Mol Diagn (2010) 1.01

Migfilin protein promotes migration and invasion in human glioma through epidermal growth factor receptor-mediated phospholipase C-γ and STAT3 protein signaling pathways. J Biol Chem (2012) 1.00

New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma. Int J Med Sci (2015) 1.00

DNA repair after irradiation in glioma cells and normal human astrocytes. Neuro Oncol (2007) 0.99

Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother (2009) 0.98

Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. Onco Targets Ther (2013) 0.97

Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells. BMC Cancer (2013) 0.96

p53 in the CNS: Perspectives on Development, Stem Cells, and Cancer. Genes Cancer (2011) 0.96

TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. Oncotarget (2015) 0.96

Aberrant signaling pathways in glioma. Cancers (Basel) (2011) 0.96

MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34

CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev (1999) 24.83

Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 17.40

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem (1998) 17.36

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15.38

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med (1997) 12.65

Genetic pathways to glioblastoma: a population-based study. Cancer Res (2004) 8.87

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33

Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science (1998) 6.62

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol (2005) 6.16

Epidemiology and etiology of gliomas. Acta Neuropathol (2005) 6.14

The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J (1998) 6.08

Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A (1998) 5.74

Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A (1992) 5.53

P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A (1997) 5.32

Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol (1996) 4.18

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem (1997) 4.03

Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res (2006) 3.41

Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci U S A (1990) 3.20

Persistence of O6-ethylguanine in rat-brain DNA: correlation with nervous system-specific carcinogenesis by ethylnitrosourea. Proc Natl Acad Sci U S A (1974) 3.07

Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res (2000) 3.05

Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev (1994) 2.88

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res (2000) 2.79

Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res (1993) 2.65

Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol (2006) 2.51

A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res (1995) 2.23

Hans-Joachim Scherer (1906-1945), pioneer in glioma research. Brain Pathol (1999) 2.20

DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet (1997) 2.18

Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res (1992) 2.17

Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol (2004) 2.15

Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res (2003) 2.15

Characterization of MAD2B and other mitotic spindle checkpoint genes. Genomics (1999) 2.01

PTEN, a unique tumor suppressor gene. Endocr Relat Cancer (2000) 1.95

Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol (2001) 1.91

Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res (1997) 1.77

A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors. Oncogene (1998) 1.72

Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis (2001) 1.71

Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res (1997) 1.71

The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays (1993) 1.70

Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol (1997) 1.68

Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res (1996) 1.68

Pten signaling in gliomas. Neuro Oncol (2002) 1.62

Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res (2002) 1.61

Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest (2000) 1.59

Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol (2004) 1.59

Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest (2001) 1.54

PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol (1998) 1.52

Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene (1995) 1.49

Mutation of the MXI1 gene in prostate cancer. Nat Genet (1995) 1.42

Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol (1993) 1.39

Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol (1997) 1.37

Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene (2005) 1.36

Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. Neuropathol Appl Neurobiol (2002) 1.35

Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res (2002) 1.33

Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma. Br J Cancer (2006) 1.29

Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas. Lab Invest (2005) 1.29

Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer (1998) 1.29

Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer (2006) 1.28

p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol (2001) 1.27

Molecular characterization of abLIM, a novel actin-binding and double zinc finger protein. J Cell Biol (1997) 1.25

Chemical carcinogenesis in the nervous system. Preferential accumulation of O6-methylguanine in rat brain deoxyribonucleic acid during repetitive administration of N-methyl-N-nitrosourea. Biochem J (1975) 1.24

PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol (2007) 1.23

Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol (1997) 1.19

Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene (2004) 1.18

O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res (2001) 1.16

Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol (1997) 1.14

Identification of a human homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region. Oncogene (1998) 1.14

Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Am J Pathol (1999) 1.11

The p53 gene and its role in human brain tumors. Glia (1995) 1.11

Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol (2000) 1.04

Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J Neuropathol Exp Neurol (1998) 1.03

Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme. Int J Oncol (1998) 1.02

Limatin (LIMAB1), an actin-binding LIM protein, maps to mouse chromosome 19 and human chromosome 10q25, a region frequently deleted in human cancers. Genomics (1997) 0.96

The prognostic impact of prior low grade histology in patients with anaplastic gliomas: a case-control study. Neurology (1996) 0.94

Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas. Int J Cancer (1997) 0.94

Chemical neuro-oncogenesis: role of structural DNA modifications, DNA repair and neural target cell population. Prog Exp Tumor Res (1984) 0.91

Clinical outcome of supratentorial astrocytoma WHO grade II. Acta Neurochir (Wien) (1998) 0.87

Coamplification of simple repetitive DNA fingerprint fragments and the EGFR gene in human gliomas. Genes Chromosomes Cancer (1991) 0.86

The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11

Genetic pathways to glioblastoma: a population-based study. Cancer Res (2004) 8.87

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol (2009) 6.43

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol (2005) 6.16

Epidemiology and etiology of gliomas. Acta Neuropathol (2005) 6.14

The definition of primary and secondary glioblastoma. Clin Cancer Res (2012) 3.84

Integrity of the conduct of the IARC monographs program. Int J Occup Environ Health (2003) 3.55

International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res (2009) 2.95

Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci (2009) 2.75

Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology (2009) 2.44

Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol (2004) 2.15

Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res (2003) 2.08

The science and practice of carcinogen identification and evaluation. Environ Health Perspect (2004) 1.89

A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg (2003) 1.60

Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol (2004) 1.59

Molecular classification of low-grade diffuse gliomas. Am J Pathol (2010) 1.51

TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol (2013) 1.51

Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol (2001) 1.38

PTEN methylation and expression in glioblastomas. Acta Neuropathol (2003) 1.31

Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice. Am J Pathol (2003) 1.28

Molecular pathogenesis of astrocytic tumours. J Neurooncol (2004) 1.24

Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol (2011) 1.18

AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene (2003) 1.13

Stratification of medulloblastoma on the basis of histopathological grading. Acta Neuropathol (2006) 1.01

Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res (2002) 0.99

Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol (2009) 0.97

Genetic profiling of CNS tumors extends histological classification. Acta Neuropathol (2010) 0.94

Intratumoral patterns of genomic imbalance in glioblastomas. Brain Pathol (2010) 0.94

Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene (2004) 0.89

Methylation of the p73 gene in gliomas. Acta Neuropathol (2002) 0.87

Brain tumors in S100beta-v-erbB transgenic rats. J Neuropathol Exp Neurol (2006) 0.82

Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them? Front Neurol (2013) 0.82

Definition of primary and secondary glioblastoma--response. Clin Cancer Res (2014) 0.82

Cerebellar liponeurocytoma with an unusually aggressive clinical course: case report. Neurosurgery (2003) 0.81

Endogenous deoxyribonucleic Acid (DNA) damage in human tissues: a comparison of ethenobases with aldehydic DNA lesions. Cancer Epidemiol Biomarkers Prev (2003) 0.80

Genetic and expression profiles of cerebellar liponeurocytomas. Brain Pathol (2004) 0.80

Transparency at the International Agency for Research on Cancer (IARC). Lancet (2003) 0.75

Reply to Dr. Sass. Int J Occup Environ Health (2003) 0.75

Reply to Marc Scherer. Brain Pathol (2013) 0.75

Alterations of the RRAS and ERCC1 genes at 19q13 in gemistocytic astrocytomas. J Neuropathol Exp Neurol (2014) 0.75

Nutrition and cancer: a complex relationship. IARC Sci Publ (2002) 0.75